Factors that might cause such a difference include, but are not limited to, those discussed in our quarterly and Annual Reports filed with the SEC. Copies of these documents are available upon request from Investor Relations at Senomyx or may be accessed via our website at www.senomyx.com.I’d now like to turn the discussion over to Kent Snyder, CEO of Senomyx. Kent Snyder Thank you, Gwen. Good morning to everyone and thank you for joining the Senomyx management team for our conference call and webcast. During this call, we’ll provide you with a general business and financial update for the second quarter of 2011. This will be followed by a question-and-answer session. I’m very pleased to report that Senomyx had important commercialization and research and development accomplishment this past quarter as well as improved financial results from operations compared to the previous year. I’ll start the call by discussing our recent achievements in Senomyx Sweet Taste Program most significantly beginning in the second quarter our commercialization partner Firmenich received initial orders for S6973. As you may recall S6973 allows sucrose to be reduced in products by up to 50% while maintaining the desired taste of natural sugar. We are impressed with Firmenich’s capabilities and efforts in introducing S6973 to top tier clients for use in a wide spectrum of product category. Later in the call, John will discuss ongoing marketing activities and our expectations for additional orders during the year. Firmenich is also continuing marketing efforts for S2383, Senomyx enhancer of the artificial sweetener sucralose. S2383 can be used in foods and beverages to enable up to a 75% reduction in the concentration of sucralose, with improved taste characteristics in some applications. It is rewarding that products containing S2383 are now on the shelves in North America. Firmenich is working with a number of clients for commercialization of other branded products utilizing S2383.